Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation

Transfusion

Volumn 50, Issue 2, 2010, Pages 407-417

  Yang, Jie ^a   Gao, Li ^a   Liu, Yan ^a   Ren, Yana ^a   Xie, Rufeng ^a   Fan, Huahua ^a   Qian, Kaicheng ^a  

^a Shanghai Blood Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5;

ACUTE GRAFT VERSUS HOST DISEASE; ADOPTIVE TRANSFER; ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CYTOKINE PRODUCTION; HISTOINCOMPATIBILITY; HISTOPATHOLOGY; IRRADIATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; SPLEEN CELL; SURVIVAL;

ACUTE DISEASE; ANIMALS; BONE MARROW TRANSPLANTATION; CELLS, CULTURED; GALACTOSYLCERAMIDES; GENE REARRANGEMENT, ALPHA-CHAIN T-CELL ANTIGEN RECEPTOR; GRAFT VS HOST DISEASE; HAIR COLOR; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; INTERLEUKIN-2; INTERLEUKIN-4; INTERLEUKIN-5; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; NATURAL KILLER T-CELLS; RADIATION CHIMERA; SPLEEN; TRANSPLANTATION, HOMOLOGOUS;

EID: 75749149739     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02395.x     Document Type: Article

References (41)

1. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol 2007 7 : 340 52.
2. Korngold B, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J. Exp. Med. 1978 148 : 1687.
3. Sun Y, Tawara I, Toubai T, Reddy P. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res. 2007 150 : 197 214. Epub 2007 July 3.
4. Messina C, Faraci M, de Fazio V, Dini G, Calò MP, Calore E EBMT Paediatric Working Party. Prevention and treatment of acute GvHD. Bone Marrow Transplant 2008 41 Suppl 2 : S65 70.
5. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 2004 4 : 371 80.
6. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008 112 : 4371 83.
7. Dickinson AM, Holler E. Polymorphisms of cytokine and innate immunity genes and GVHD. Best Pract Res Clin Haematol 2008 21 : 149 64.
8. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000 95 : 2754 9.
9. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today 2000 21 : 573 83.
10. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004 4 : 231 7.
11. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007 25 : 297 336.
12. Wilson MT, Singh AK, Van Kaer L. Immunotherapy with ligands of natural killer T cells. Trends Mol Med 2002 8 : 225 31.
13. Tsuji M. Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands. Cell Mol Life Sci 2006 63 : 1889 98.
14. Silk JD, Salio M, Brown J, Jones EY, Cerundolo V. Structural and functional aspects of lipid binding by CD1 molecules. Annu Rev Cell Dev Biol 2008 24 : 369 95.
15. Dickinson AM, Holler E. Polymorphisms of cytokine and innate immunity genes and GVHD. Best Pract Res Clin Haematol. 2008 21 : 149 64.
16. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003 21 : 483 513.
17. Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L. CD1d-restricted iNKT cells, the "Swiss-Army knife" of the immune system. Curr Opin Immunol 2008 20 : 358 68.
18. Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009 9 : 28 38.
19. + T cells reciprocally regulate acute graft versus host disease. J Exp Med 1999 189 : 1073.
20. Haraguchi K, Takahashi T, Matsumoto A, Asai T, Kanda Y, Kurokawa M, Ogawa S, Oda H, Taniguchi M, Hirai H, Chiba S. Host-residual invariant NK T cells attenuate graft-versus-host immunity. J Immunol 2005 175 : 1320 8.
21. Hashimoto D, Asakura S, Miyake S, Yamamura T, Van Kaer L, Liu C, Tanimoto M, Teshima T. Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells. J Immunol 2005 174 : 551 6.
22. Pillai AB, George TI, Dutt S, Teo P, Strober S. Host NKT cells can prevent graft-versus-host Dis and permit graft antitumor activity after bone marrow transplantation. J Immunol 2007 178 : 6242 51.
23. +Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004 103 : 383 9.
24. Watarai H, Nakagawa R, Omori-Miyake M, Dashtsoodol N, Taniguchi M. Methods for detection, isolation and culture of mouse and human invariant NKT cells. Nat Protoc 2008 3 : 70 8.
25. Haraguchi K, Takahashi T, Hiruma K, Kanda Y, Tanaka Y, Ogawa S, Chiba S, Miura O, Sakamaki H, Hirai H. Recovery of Valpha24+ NKT cells after hematopoietic stem cell transplantation. Bone Marrow Transplant 2004 34 : 595 602. (Pubitemid 39341539)
26. Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J Jr., Crawford JM, Ferrara JL. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 1996 88 : 3230 9.
27. Kaplan DH, Anderson BE, McNiff JM, Jain D, Shlomchik MJ, Shlomchik WD. Target antigens determine graft-versus-host disease phenotype. J Immunol 2004 173 : 5467 75.
28. Seino K, Fukao K, Muramoto K, Yanagisawa K, Takada Y, Kakuta S, Iwakura Y, Van Kaer L, Takeda K, Nakayama T, Taniguchi M, Bashuda H, Yagita H, Okumura K. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc Natl Acad Sci U S A 2001 98 : 2577 81.
29. Chargui J, Hase T, Wada S, Naganuma T, Yoshimura R. NKT cells as nonspecific immune-regulator inducing tolerance in mouse model transplantation. Transpl Proc 2001 33 : 3833 4.
30. Oh SJ, Kim JH, Min CK, Chung DH. Role of type II NKT cells in the suppression of graft-versus-host disease. Crit Rev Immunol 2008 28 : 249 67.
31. Kim JH, Choi EY, Chung DH. Donor bone marrow type II (non- Valpha14Jalpha18 CD1d-restricted) NKT cells suppress graft-versus-host disease by producing IFN-gamma and IL-4. J Immunol 2007 179 6579 87.
32. Krenger W, Snyder KM, Byon JC, Falzarano G, Ferrara JL. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J. Immunol 1995 155 : 585 93.
33. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 2001 29 : 259 77.
34. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001 413 : 531 4.
35. Oki S, Chiba A, Yamamura T, Miyake S. The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid stimulated NKT cells. J Clin Invest 2004 113 : 1631.
36. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008 133 : 775 87.
37. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008 8 : 523 32.
38. Pillai AB, George TI, Dutt S, Strober S. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. Blood 2009 113 : 4458 67.
39. Nicol A, Nieda M, Koezuka Y, Porcelli S, Suzuki K, Tadokoro K, Durrant S, Juji T. Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells. Immunology 2000 99 : 229 34.
40. Ambrosino E, Berzofsky JA, Terabe M. Regulation of tumor immunity: the role of NKT cells. Expert Opin Biol Ther 2008 8 : 725 34.
41. Motohashi S, Nakayama T. Clinical applications of natural killer T cell-based immunotherapy for cancer. Cancer Sci 2008 99 : 638 45. Epub 2008 Feb 21.